CN118973572A - 用于治疗癌症的组合疗法 - Google Patents

用于治疗癌症的组合疗法 Download PDF

Info

Publication number
CN118973572A
CN118973572A CN202380032429.6A CN202380032429A CN118973572A CN 118973572 A CN118973572 A CN 118973572A CN 202380032429 A CN202380032429 A CN 202380032429A CN 118973572 A CN118973572 A CN 118973572A
Authority
CN
China
Prior art keywords
azd5305
pharmaceutically acceptable
acceptable salt
prostate cancer
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380032429.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·C·科苏利奇
J·S·布朗
M·R·阿尔伯特拉
E·李奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN118973572A publication Critical patent/CN118973572A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380032429.6A 2022-04-07 2023-04-06 用于治疗癌症的组合疗法 Pending CN118973572A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362612P 2022-04-07 2022-04-07
US63/362612 2022-04-07
PCT/EP2023/059126 WO2023194528A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
CN118973572A true CN118973572A (zh) 2024-11-15

Family

ID=86185292

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380032429.6A Pending CN118973572A (zh) 2022-04-07 2023-04-06 用于治疗癌症的组合疗法

Country Status (11)

Country Link
US (1) US20250235448A1 (https=)
EP (1) EP4504180A1 (https=)
JP (1) JP2025511401A (https=)
KR (1) KR20240170956A (https=)
CN (1) CN118973572A (https=)
AU (1) AU2023248685A1 (https=)
CA (1) CA3254948A1 (https=)
IL (1) IL316016A (https=)
MX (1) MX2024012368A (https=)
TW (1) TW202404593A (https=)
WO (1) WO2023194528A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026021478A1 (zh) * 2024-07-23 2026-01-29 江苏恒瑞医药股份有限公司 Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
MX2022000711A (es) 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法

Also Published As

Publication number Publication date
MX2024012368A (es) 2024-11-08
AU2023248685A1 (en) 2024-11-14
IL316016A (en) 2024-11-01
TW202404593A (zh) 2024-02-01
US20250235448A1 (en) 2025-07-24
EP4504180A1 (en) 2025-02-12
JP2025511401A (ja) 2025-04-15
KR20240170956A (ko) 2024-12-05
CA3254948A1 (en) 2023-10-12
WO2023194528A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
AU2013205648B2 (en) Combination treatment
CN118973572A (zh) 用于治疗癌症的组合疗法
CN119212702A (zh) 用于治疗癌症的组合疗法
KR102005887B1 (ko) 뇌종양의 예방 또는 치료용 약학 조성물
KR20220124739A (ko) 암의 치료를 위한 병용 요법
CN118973555A (zh) 用于治疗癌症的组合疗法
CA3245251A1 (en) TREATMENT METHOD COMPRISING KRAS G12C INHIBITORS AND SHP2 INHIBITORS
KR20260010420A (ko) 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용
US20250222003A1 (en) Pharmaceutical composition for treating solid tumors
KR20260020107A (ko) 다발성 경화증을 치료하기 위한 btk 억제제
US20060009475A1 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
KR20240148328A (ko) 전이성 거세 저항성 전립선암 및 hrr 변형을 갖는 환자에서 임상 결과를 개선하기 위한 니라파립 및 아비라테론 아세테이트와 프레드니손
JP2024542831A (ja) Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法
CN118542942A (zh) Pd-l1小分子抑制剂与抗体的药物组合及其应用
HK1185808B (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
HK1185808A1 (zh) 用於治疗癌症的包含威罗菲尼和干扰素的组合疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination